BMI1 and acute myeloid leukemia: Recently, Bmi-1 has been the focus of significant clinical interest because studies have demonstrated its upregulation in various malignancies such as non-small cell lung cancer [17], breast cancer [18, 19] and colorectal cancer [20], as well as hematological malignancies including mantle cell lymphoma [21], B cell non-Hodgkin’s lymphoma [22] and acute myeloid leukemia (AML) [23].